Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Investing Activities (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Cash from Investing Activities data on record, last reported at -$47.5 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 405.46% year-over-year to -$47.5 million; the TTM value through Dec 2025 reached -$3.7 million, up 94.68%, while the annual FY2025 figure was -$3.7 million, 94.68% up from the prior year.
  • Cash from Investing Activities reached -$47.5 million in Q4 2025 per CTNM's latest filing, down from $14.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $14.9 million in Q3 2025 and bottomed at -$47.5 million in Q4 2025.
  • Average Cash from Investing Activities over 3 years is -$11.6 million, with a median of -$328500.0 recorded in 2024.
  • The widest YoY moves for Cash from Investing Activities: up 149.5% in 2025, down 405.46% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at $9.0 million in 2023, then plummeted by 203.96% to -$9.4 million in 2024, then tumbled by 405.46% to -$47.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$47.5 million in Q4 2025, $14.9 million in Q3 2025, and $13.9 million in Q2 2025.